Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...That time Pfizer failed to clinch a deal for AstraZeneca If Ian Read had his way, AstraZeneca would be a unit of US pharma group Pfizer right now....
...The sale of the 36.5 per cent share is part of a realignment taking place in the global consumer healthcare sector, which has also seen Pfizer of the US put its consumer healthcare unit up for sale....
...The “consideration and detailed review that we did around Pfizer assets opened up this opportunity and we are both very happy to conclude it”, she said....
...Nestlé was mentioned as a possible buyer for German drug company Merck’s consumer healthcare business or US group Pfizer’s consumer unit. But coffee has become the immediate priority....
...Nestlé is considered a potential buyer for the healthcare assets of German drugmaker Merck and those of Pfizer....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...The latest data extended the V-shaped recovery in eurozone industrial production since April....
...It has since staged a “v-shaped” revival, pointing to a robust recovery....
...Their v-shaped recovery pointed to a “very quick unwinding of the confidence shock, which could overshoot”, argued Jacques Cailloux, European economist at the Royal Bank of Scotland....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...The US, China, Germany and France reported further strong improvements, adding to evidence of a v-shaped recovery in economic growth in the third quarter....
...Andreas Rees, economist at Unicredit in Munich, argued the “v-shaped” recovery in the ZEW index since October has been partly psychologically-driven, after an economic meltdown was averted....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...However, depending on the relative strength of financial markets and the real economy, it might adopt a different exit sequence in the V-shaped recovery scenario, tightening rates before financial market...
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...Paul Atkins, an SEC commissioner, urged the court to take the case Billing v Credit Suisse First Boston, saying that such lawsuits “could devastate America’s process of capital formation, wreak unprecedented...
...MedImmune Inc. v. Genentech, Inc. has an enormous bearing on the intellectual integrity of patent licenses. This saga starts with the famous 1969 decision in Lear v....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition